Pharming Group's G&A Expense Reduction Strategy
Pharming Group N.V. announces a strategic initiative aimed at streamlining operations and fostering growth. The company undertakes a restructuring process aligned with its goal to optimize general and administrative (G&A) expenses, enhancing capital allocation company-wide.
Restructuring for Growth
The recent restructuring measures include a complete overhaul of Pharming's organizational framework. This modification involves achieving a notable 20% reduction in non-commercial and non-medical personnel, predominantly affecting the team at its headquarters. The company is on track to lower total G&A costs by 15%, projecting an annual saving of approximately US$10 million. This move also anticipates non-recurring restructuring expenses, estimated at about $7 million, which are expected to be recognized in the fourth quarter of the fiscal year 2025.
Dialogue with Stakeholders
Mindful of the impact of such changes, Pharming has engaged in consultations with its Dutch Works Council over the past months. This adherence to Dutch labor laws underscores the company's commitment to transparent and respectful organizational change.
About Pharming Group N.V.
Pharming Group N.V. (NASDAQ: PHAR) is a pioneering biopharmaceutical firm focused on improving the quality of life for patients suffering from rare and severe diseases. The company is dedicated to both developing and commercializing a diverse range of innovative therapies, which consist of small molecules and biologics. While Pharming is based in Leiden, it boasts a significant number of its employees located in the United States, fostering a diverse and dedicated workforce.
Future Directions and Outlook
As Pharming navigates through these changes, its primary focus remains on enhancing efficiencies and innovating in its product offerings. The organization continuously seeks ways to support its strategic objectives as it moves forward. Investors and stakeholders can look forward to increased communication regarding progress and future opportunities that may arise as a result of these changes.
Contact Information
For more inquiries, interested parties may reach out to Pharming Group in Leiden, the Netherlands. Michael Levitan serves as the VP of Investor Relations and Corporate Communications, and can be contacted at +1 (908) 705 1696. Additionally, Saskia Mehring, the Corporate Communications Manager, is available at +31 6 28 32 60 41. For any investor-related questions, you may email investor@pharming.com.
Frequently Asked Questions
What is the purpose of Pharming's recent restructuring?
The restructuring is designed to optimize operations, reduce G&A expenses, and promote growth within the company.
What impact will the restructuring have on employees?
A 20% reduction in non-commercial and non-medical headcount is anticipated, primarily affecting the headquarters staff.
How much does Pharming expect to save from the G&A reduction?
The company aims to achieve a 15% reduction in total G&A costs, translating to an annual saving of approximately US$10 million.
What are the anticipated one-time costs associated with the restructuring?
Pharming estimates one-time restructuring costs to be around $7 million, which will be recorded in the fourth quarter of 2025.
How can investors get more information about Pharming's activities?
Investors can find more information by visiting Pharming's official website or contacting the Investor Relations department directly.
